Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NSCLC
Pharma
FDA christens Hyrnuo a first-line option for rare lung cancer
The FDA expanded Hyrnuo's indication to include first-line treatment, amping up the med's rivalry with Boehringer Ingelheim's Hernexeos.
Donavyn Coffey
Sep 9, 2026 4:33pm
Boehringer's lung cancer med passes muster with the FDA
Aug 8, 2025 3:52pm
Merus' Bizengri wins FDA nod as 1st drug to target NRG1+ cancers
Dec 4, 2024 6:55pm
BMS' Opdivo widens lung cancer reach with perioperative FDA nod
Oct 3, 2024 3:54pm
FDA's ODAC calls for revamp of perioperative NSCLC trials
Jul 25, 2024 5:00pm
Boehringer Ingelheim preps for 2 upcoming oncology launches
Jun 10, 2024 8:20am
